United Therapeutics Corp. Daily Stock Analysis

Daily Stock Analysis, UTHR, United Therapeutics Corp, priceseries

United Therapeutics Corp. Daily Stock Analysis
Stock Information
Open
173.55
Close
172.85
High
175.93
Low
171.12
Previous Close
174.52
Daily Price Gain
-1.67
YTD High
217.84
YTD High Date
Jan 18, 2022
YTD Low
161.23
YTD Low Date
Feb 24, 2022
YTD Price Change
-37.78
YTD Gain
-17.94%
52 Week High
218.38
52 Week High Date
Dec 31, 2021
52 Week Low
155.71
52 Week Low Date
Mar 12, 2021
52 Week Price Change
12.76
52 Week Gain
7.97%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
153.00
Feb 22. 2017
160.92
21 Trading Days
5.18%
Link
LONG
Nov 28. 2017
124.55
Dec 21. 2017
135.36
17 Trading Days
8.68%
Link
LONG
Dec 22. 2017
137.25
Jan 10. 2018
145.80
11 Trading Days
6.23%
Link
LONG
Jul 3. 2018
116.41
Jul 27. 2018
122.29
17 Trading Days
5.05%
Link
LONG
Oct 25. 2019
84.07
Nov 12. 2019
89.89
12 Trading Days
6.92%
Link
LONG
Feb 4. 2020
96.65
Feb 26. 2020
106.24
15 Trading Days
9.92%
Link
LONG
Oct 13. 2020
108.32
Nov 18. 2020
137.38
26 Trading Days
26.83%
Link
LONG
Dec 10. 2020
137.21
Jan 26. 2021
164.40
30 Trading Days
19.81%
Link
Company Information
Stock Symbol
UTHR
Exchange
NasdaqGS
Company URL
http://www.unither.com
Company Phone
3016089292
CEO
Martine A. Rothblatt
Headquarters
Maryland
Business Address
1040 SPRING ST, SILVER SPRING, MD 20910
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001082554
About

United Therapeutics Corp. operates as a biotechnology company. The company is engaged in development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Description

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading